本页面由Tiger Trade Technology Pte. Ltd.提供服务

Mesoblast Limited

16.91
-0.1300-0.76%
盘后16.910.00000.00%16:10 EST
成交量:7.20万
成交额:121.35万
市值:21.69亿
市盈率:-19.99
高:16.96
开:16.88
低:16.71
收:17.04
52周最高:21.50
52周最低:9.61
股本:1.28亿
流通股本:7,864.91万
量比:0.37
换手率:0.09%
股息:- -
股息率:- -
每股收益(TTM):-0.8460
每股收益(LYR):-0.8457
净资产收益率:-18.95%
总资产收益率:-5.37%
市净率:3.63
市盈率(LYR):-20.00

数据加载中...

公司资料

公司名字:
Mesoblast Limited
交易所:
NASDAQ
成立时间:
2004
员工人数:
81
公司地址:
55 Collins Street,Level 38,Melbourne,Victoria,Australia
邮编:
3000
传真:
61 3 9639 6030
简介:
Mesoblast Limited于2004年6月8日在澳大利亚成立。该公司在开发同种异体细胞药物方面处于世界领先地位。该公司利用其专有的间充质谱系细胞治疗技术平台建立了广泛的商业产品和后期产品候选产品组合。

董事

名称
职位
Silviu Itescu
Chief Executive Officer and Executive Director
Eric Rose
Chief Medical Officer and Executive Director
Jane Bell
Independent Chair of Board

股东

名称
职位
Paul Simmons
Scientific Advisor to the Chief Executive Officer
Silviu Itescu
Chief Executive Officer and Executive Director
Andrew Chaponnel
Chief Financial Officer
Eric Rose
Chief Medical Officer and Executive Director
Fiona See
Head of Translational Research
Geraldine Storton
Head of Regulatory Affairs and Quality Management
Gregory George
Non-Executive Member of the Board
Joseph Swedish
Non-Executive Member of the Board
Justin Horst
Head of Manufacturing
Lyn Cobley
Non-Executive Member of the Board
Michael Schuster
Pharma Partnering
Niva Sivakumar
Joint Company Secretary
Paul Hughes
Joint Company Secretary
Peter Howard
Group General Counsel and Corporate Executive
Philip Facchina
Non-Executive Member of the Board
Philip Krause
Non-Executive Member of the Board
William Burns
Non-Executive Member of the Board